Edgar Filing: MEDICINES CO /DE - Form 8-K

MEDICINES CO /DE Form 8-K October 21, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): OCTOBER 21, 2003

THE MEDICINES COMPANY ______ (Exact Name of Registrant as Specified in Charter) DELAWARE 000-31191 04-3324394 -----._____ -----(State or Other Jurisdiction (Commission (Commission (IRS Employer File Number) Identification No.) of Incorporation) 8 CAMPUS DRIVE PARSIPPANY, NEW JERSEY 07054 _____ _____ (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (973) 656-1616 (Former Name or Former Address, if Changed Since Last Report)

ITEM 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On October 21, 2003, The Medicines Company (the "Company") announced its financial results for the quarter ended September 30, 2003. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities

Edgar Filing: MEDICINES CO /DE - Form 8-K

Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: October 21, 2003 By: /s/ Steven H. Koehler

Steven H. Koehler

Vice President and Chief Financial

Officer

Results."

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press release dated October 21, 2003
entitled "The Medicines Company
Reports Third Quarter 2003 Financial